Skip to main content

Market Overview

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Share:
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
  • Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and select Asian markets.
  • Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and Eosinophilic Esophagitis (EoE).
  • NX-13 is a novel, oral, gut-restricted NLRX1 targeting compound in development to treat UC and CD.
  • Under the terms of the collaboration, Landos will receive an upfront cash payment of $18 million and is eligible to receive milestone payments of up to $200 million.
  • Landos is also eligible to receive tiered low double-digit royalties.
  • LianBio will fund development and commercialization expenses in the collaboration territory, and Landos will continue to fund all development and commercialization expenses in all other geographies.
  • Landos reported a Q1 loss of $(9.8) million, higher than the $5.8 million reported a year ago.
  • The company held cash and equivalents of $106.4 million.
  • Price Action: LABP shares are up 2.58% at $11.95 in the premarket session on the last check Monday.
 

Related Articles (LABP)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com